Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 11—November 2008

Dispatch

Growth and Geographic Variation in Hospitalizations with Resistant Infections, United States, 2000–2005

Marya D. ZilberbergComments to Author , Andrew F. Shorr, and Marin H. Kollef
Author affiliations: EviMed Research Group, LLC, Goshen, Massachussetts, USA (M.D. Zilberberg); University of Massachusetts, Amherst, Massachusetts, USA (M.D. Zilberberg); Washington Hospital Center, Washington, DC, USA (A.F. Shorr)Barnes Jewish Hospital, St. Louis, Missouri, USA (M.H. Kollef);

Suggested citation for this article

Abstract

From 2000 through 2005, hospitalizations with resistant infections (methicillin-resistant Staphylococcus aureus, Clostridium difficile–associated disease, vancomycin-resistant enterococcus, Pseudomonas aeruginosa, and Candida infection) nearly doubled, from 499,702 to 947,393. Regional variations noted in the aggregate and by individual infection may help clarify modifiable risk factors driving these infections.

Over the past decade we have witnessed a rise in the antimicrobial drug–resistance epidemic in the United States and worldwide. Not only are resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile encountered with increasing frequency (1,2), but as their susceptibility to antimicrobial agents is waning, their overall virulence is on the rise (3,4). Additionally, though traditionally thought of as a nosocomial pathogen, MRSA, for example, is now a well-recognized community-acquired infection (5).

With the rapid growth of resistance, and the added associated illnesses and deaths (6,7), these infections exert a considerable strain on the US healthcare system, specifically on hospitals. Although important to understand for individual infections, the aggregate volume of resistance is an important factor in illustrating the problem as a whole and in helping identify the potential resources needed to deal with the epidemic. To understand the full extent of resistant infections in US hospitals, we examined their longitudinal trends from 2000 through 2005, focusing further on regional patterns of resistance during this time frame.

The Study

We identified all hospitalizations carrying a diagnosis of MRSA, Clostridium difficile–associated disease (CDAD), vancomycin-resistant enterococcus (VRE), Pseudomonas aeruginosa, and Candida infections for 2000–2005 from the National Inpatient Sample data. These data are available on the Healthcare Costs and Utilization Project net [HCUPnet] website, administered by the Agency for Healthcare Research and Quality (8). We used the corresponding diagnosis codes from the International Classification of Diseases, 9th revision, Clinical Modification (Appendix Table [PDF - 13 KB - 1 page]). Because few reports of vancomycin-resistant Staphylococcus aureus exist (9), we assumed that most cases with the code V09.8 represented VRE infections. We limited hospitalizations in which Candida organisms had been identified to deep-seated infections, including candidiasis of the lung, disseminated candidiasis, candidal endocarditis, meningitis, esophagitis, and enteritis. The numbers of discharges per year for infections associated with each organism and in aggregate were stratified by census region. We obtained regional estimates of all US hospitalizations in the corresponding years from the HCUPNet (8), and censal and intercensal data on the US population for 2000–2005 from the US Census Bureau. We calculated region-specific hospitalization incidence rates associated with the resistant pathogens. Because large numbers would predispose the study to type I error, we did not perform formal significance testing; rather, we focused on clinical and policy-relevant trends.

The overall volume of resistant infections increased by 89.6% from year 2000 through 2005 (Table). As a proportion of the total volume growth, the increases across regions were comparable. The southern region had the highest raw volume of resistant infections for the study period (2000, 37.3%; 2005, 39.1%). The West had the smallest contribution in 2000 (19.0%) and 2005 (19.5%). However, the Northeast had the highest relative incidence per 1,000 hospitalizations with 14.00 in year 2000; its incidence of 19.98 in 2005, however, was lower than that in the South, 20.76/1,000 (Table). Regional disparities in the population-based incidence of hospitalizations with resistant organisms also occurred (Table). Thus, the incidence in the Northeast was not only the highest for 5 of the 6 years examined, but compared to that seen in the lowest-incidence region, the West, was higher by as much as 41.9% in 2003. This gap shrank in 2004 and 2005 to 29.9% and 27.7%, respectively.

Figure

Thumbnail of Population incidence of component resistant infections in the United States, by census region, 2000–2005. A) Clostridium difficile–associated disease; B) methicillin-resistant Staphylococcus aureus; C) vancomycin-resistant enterococcus; D) Pseudomonas aeruginosa; E) Candida spp.

Figure. Population incidence of component resistant infections in the United States, by census region, 2000–2005. A) Clostridium difficile–associated disease; B) methicillin-resistant Staphylococcus aureus; C) vancomycin-resistant enterococcus; D) Pseudomonas aeruginosa; E) Candida spp.

When the incidences of individual component infections were examined, several patterns emerged. While the Northeast led other regions in the incidence of CDAD hospitalizations over the entire period examined (Figure, panel A), the South exhibited the highest population incidence of MRSA and Pseudomonas hospitalizations. Although temporal patterns of regional population incidence varied somewhat for hospitalizations in which VRE and Candida spp. infections were diagnosed, by year 2005 the Northeast emerged as the region with the highest incidence of VRE, while the South had the highest incidence of Candida spp. hospitalizations. The lowest incidence of VRE hospitalizations was consistently seen in the southern region in each of the studied years. The incidence of hospitalizations with pseudomonal infections remained relatively stable regionally over time (Figure, panels B, C, D).

Conclusions

We have demonstrated a substantial rise in the absolute number, incidence, and geographic variations across the United States in hospitalizations in which infections have been caused by pathogens exhibiting antimicrobial resistance. The Northeast consistently outpaced the other regions in the aggregate volume of resistant infections in 5 of the 6 years examined. For individual infections, a region’s having a relatively high incidence of 1 organism does not guarantee it will have a high incidence of another organism, as illustrated by the reversal of the regional incidence patterns for MRSA and CDAD, for example. Most troubling, however, is the general finding of a ubiquitous, substantial, and continuing increase in the incidence of hospitalizations with resistant infections.

A notable pattern in our study is that the regions with the higher incidence of CDAD (Northeast and Midwest) also exhibited higher incidence of VRE in at least half of the study period, consistent with the observation that infection with CDAD can facilitate transmission of VRE (10,11). The South had the highest incidence of MRSA and lowest incidence of VRE. Since both pathogens share similar risk factors, why this pattern should be present is biologically unclear (12,13), although a recent report noted a similar pattern of concomitant increases in MRSA and decreases in VRE incidence between 1999 through 2005 (14). This potential inverse relationship should be investigated further. Lastly, we noted that, although substantially discrepant regionally, the incidence of hospitalizations with P. aeruginosa infections, consistent with others’ observations, has remained relatively stable over the 6-year period (15). We cannot illuminate the reasons for the patterns of infection incidences we have uncovered. Further studies should encompass much more granular geographic data to confirm our findings and raise hypotheses to explain them.

The most important limitation of our study is that case ascertainment was performed by using administrative coding, rather than clinical and microbiologic data, and we were unable to verify diagnostic accuracy either across time or geographic areas; therefore, the observed increases may be partially due to increased awareness of resistance. However, administrative coding has been used to track the epidemiology of both MRSA and CDAD (1,2). Furthermore, temporal trends in case volume are similar to trends reported from clinical studies. At least a proportion of the case-patients we identified likely had overlapping infections with multiple organisms. Nevertheless, the aggregate number of infections that we have described has implications for hospital resource use because persons with multiple infections likely require more care than those with a single pathogen. Finally, we were unable to differentiate between community-acquired and nosocomial infections.

In summary, we have demonstrated a notable increase in the incidence of hospitalizations with resistant organisms in the United States. Regional variations in the incidence may yield clues for future research efforts to ascertain what modifiable risk factors drive decreases in the incidence of these deadly infections. The nearly 1 million annual hospitalizations in 2005 with resistant infections and their relentless upward trajectory in the United States are undesirable and unsustainable. Aggressive and coordinated efforts to reduce inappropriate use of antibimicrobial agents in humans and livestock and to encourage development of novel therapeutics are urgently needed to stem this public health hazard in the United States and throughout the world.

Dr Zilberberg is a health services researcher at the University of Massachusetts, Amherst, and the president of EviMed Research Group, LLC. Her research interests include reducing complications and optimizing the efficiency of healthcare delivery in the hospital setting.

References

  1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:18406.PubMed
  2. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile–related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14:92931. DOIPubMed
  3. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60:78894. DOIPubMed
  4. Razavi B, Apisarnthanarak A, Mundy LM. Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. Infection. 2007;35:3007. DOIPubMed
  5. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:66674. DOIPubMed
  6. Shorr AF, Tabak YP, Gupta V, Johannes RS, Liu LZ, Kollef MH. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10:R97. DOIPubMed
  7. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay and health care costs. Clin Infect Dis. 2006;42:S829. DOIPubMed
  8. HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2000–2004. Rockville (MD): Agency for Healthcare Research and Quality [cited 2008 Feb 24]. Available from http://hcupnet.ahrq.gov
  9. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006. Clin Infect Dis. 2008;46:66874. DOIPubMed
  10. Tokars JI, Satake S, Rimland D, Carson L, Miller ER, Killum E, The prevalence of colonization with vancomycin-resistant Enterococcus at a Veterans’ Affairs institution. Infect Control Hosp Epidemiol. 1999;20:1715. DOIPubMed
  11. Rafferty ME, McCormick MI, Bopp LH, Baltch AL, George M, Smith RP, Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol. 1997;18:3424.PubMed
  12. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:83444.PubMed
  13. Polgreen PM, Beekmann SE, Chen YY, Epidemiology of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a rural state. Infect Control Hosp Epidemiol. 2006;27:2526. DOIPubMed
  14. Goll C, Balmer P, Schwab F, Rüden H, Eckmanns T. Different trends of MRSA and VRE in a German hospital, 1999–2005. Infection. 2007;35:2459. DOIPubMed
  15. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:84854. DOIPubMed

Figure

Tables

Suggested citation for this article: Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, United States, 2000–2005. Emerg Infect Dis [serial on the Internet]. 2008 Nov [date cited]. Available from http://wwwnc.cdc.gov/eid/article/14/11/08-0337

DOI: 10.3201/eid1411.080337

Table of Contents – Volume 14, Number 11—November 2008

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Marya D. Zilberberg, EviMed Research Group, LLC, PO Box 303, Goshen, MA 01032, USA;

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

TOP